Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer

U. De Giorgi; V. Valero; E. Rohren; M. Mego; G. V. Doyle; M. C. Miller; N. T. Ueno; B. C. Handy; J. M. Reuben; H. A. Macapinlac; G. N. Hortobagyi; M. Cristofanilli

doi:10.1093/annonc/mdp262

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer

U. De Giorgi, V. Valero, E. Rohren, M. Mego, G. V. Doyle, M. C. Miller, N. T. Ueno, B. C. Handy, J. M. Reuben, H. A. Macapinlac, G. N. Hortobagyi, M. Cristofanilli

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

Background: We evaluated the relationship between the detection and prognostic significance of circulating tumor cells (CTCs) and sites of metastases detected by 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with metastatic breast cancer (MBC). Patients and methods: From May 2004 to January 2008, 195 patients with relapsed/progressive MBC underwent whole-body FDG-PET/CT and provided blood samples for assessment of CTC count. Results: Higher CTC numbers were detected in patients with bone metastases relative to those with no bone lesions (mean 65.7 versus 3.3, P = 0.0122) and in patients with multiple bone metastases relative to those with one or two bone lesions (mean 77.7 versus 2.6, P < 0.001). CTCs predicted overall survival (OS) in 108 patients with multiple sites of metastases including bone (P = 0.0008) but not in 58 without bone metastases (P = 0.4111) and in 29 with bone involvement only (P = 0.3552). All 15 patients but one with human epidermal growth factor receptor 2 (HER-2) positive tumors who were treated with trastuzumab-based regimens had <5 CTCs at progression. In multivariate analysis, CTCs, but not bone metastases, remained a significant predictor of OS. Conclusion: Presence of extensive bone metastases as detected by FDG-PET/CT is associated with increased CTC numbers in MBC.

Original language	English (US)
Pages (from-to)	33-39
Number of pages	7
Journal	Annals of Oncology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdp262
State	Published - Jul 14 2009

Keywords

Bone metastases
Breast cancer
Circulating tumor cells
FDG-PET/CT
Prognosis

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdp262

Cite this

De Giorgi, U., Valero, V., Rohren, E., Mego, M., Doyle, G. V., Miller, M. C., Ueno, N. T., Handy, B. C., Reuben, J. M., Macapinlac, H. A., Hortobagyi, G. N., & Cristofanilli, M. (2009). Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology, 21(1), 33-39. https://doi.org/10.1093/annonc/mdp262

@article{1507c969aaeb4122a393f2797287bffe,

title = "Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer",

abstract = "Background: We evaluated the relationship between the detection and prognostic significance of circulating tumor cells (CTCs) and sites of metastases detected by 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with metastatic breast cancer (MBC). Patients and methods: From May 2004 to January 2008, 195 patients with relapsed/progressive MBC underwent whole-body FDG-PET/CT and provided blood samples for assessment of CTC count. Results: Higher CTC numbers were detected in patients with bone metastases relative to those with no bone lesions (mean 65.7 versus 3.3, P = 0.0122) and in patients with multiple bone metastases relative to those with one or two bone lesions (mean 77.7 versus 2.6, P < 0.001). CTCs predicted overall survival (OS) in 108 patients with multiple sites of metastases including bone (P = 0.0008) but not in 58 without bone metastases (P = 0.4111) and in 29 with bone involvement only (P = 0.3552). All 15 patients but one with human epidermal growth factor receptor 2 (HER-2) positive tumors who were treated with trastuzumab-based regimens had <5 CTCs at progression. In multivariate analysis, CTCs, but not bone metastases, remained a significant predictor of OS. Conclusion: Presence of extensive bone metastases as detected by FDG-PET/CT is associated with increased CTC numbers in MBC.",

keywords = "Bone metastases, Breast cancer, Circulating tumor cells, FDG-PET/CT, Prognosis",

author = "{De Giorgi}, U. and V. Valero and E. Rohren and M. Mego and Doyle, {G. V.} and Miller, {M. C.} and Ueno, {N. T.} and Handy, {B. C.} and Reuben, {J. M.} and Macapinlac, {H. A.} and Hortobagyi, {G. N.} and M. Cristofanilli",

year = "2009",

month = jul,

day = "14",

doi = "10.1093/annonc/mdp262",

language = "English (US)",

volume = "21",

pages = "33--39",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer

AU - De Giorgi, U.

AU - Valero, V.

AU - Rohren, E.

AU - Mego, M.

AU - Doyle, G. V.

AU - Miller, M. C.

AU - Ueno, N. T.

AU - Handy, B. C.

AU - Reuben, J. M.

AU - Macapinlac, H. A.

AU - Hortobagyi, G. N.

AU - Cristofanilli, M.

PY - 2009/7/14

Y1 - 2009/7/14

N2 - Background: We evaluated the relationship between the detection and prognostic significance of circulating tumor cells (CTCs) and sites of metastases detected by 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with metastatic breast cancer (MBC). Patients and methods: From May 2004 to January 2008, 195 patients with relapsed/progressive MBC underwent whole-body FDG-PET/CT and provided blood samples for assessment of CTC count. Results: Higher CTC numbers were detected in patients with bone metastases relative to those with no bone lesions (mean 65.7 versus 3.3, P = 0.0122) and in patients with multiple bone metastases relative to those with one or two bone lesions (mean 77.7 versus 2.6, P < 0.001). CTCs predicted overall survival (OS) in 108 patients with multiple sites of metastases including bone (P = 0.0008) but not in 58 without bone metastases (P = 0.4111) and in 29 with bone involvement only (P = 0.3552). All 15 patients but one with human epidermal growth factor receptor 2 (HER-2) positive tumors who were treated with trastuzumab-based regimens had <5 CTCs at progression. In multivariate analysis, CTCs, but not bone metastases, remained a significant predictor of OS. Conclusion: Presence of extensive bone metastases as detected by FDG-PET/CT is associated with increased CTC numbers in MBC.

AB - Background: We evaluated the relationship between the detection and prognostic significance of circulating tumor cells (CTCs) and sites of metastases detected by 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with metastatic breast cancer (MBC). Patients and methods: From May 2004 to January 2008, 195 patients with relapsed/progressive MBC underwent whole-body FDG-PET/CT and provided blood samples for assessment of CTC count. Results: Higher CTC numbers were detected in patients with bone metastases relative to those with no bone lesions (mean 65.7 versus 3.3, P = 0.0122) and in patients with multiple bone metastases relative to those with one or two bone lesions (mean 77.7 versus 2.6, P < 0.001). CTCs predicted overall survival (OS) in 108 patients with multiple sites of metastases including bone (P = 0.0008) but not in 58 without bone metastases (P = 0.4111) and in 29 with bone involvement only (P = 0.3552). All 15 patients but one with human epidermal growth factor receptor 2 (HER-2) positive tumors who were treated with trastuzumab-based regimens had <5 CTCs at progression. In multivariate analysis, CTCs, but not bone metastases, remained a significant predictor of OS. Conclusion: Presence of extensive bone metastases as detected by FDG-PET/CT is associated with increased CTC numbers in MBC.

KW - Bone metastases

KW - Breast cancer

KW - Circulating tumor cells

KW - FDG-PET/CT

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77949311998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949311998&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp262

DO - 10.1093/annonc/mdp262

M3 - Article

C2 - 19602564

AN - SCOPUS:77949311998

SN - 0923-7534

VL - 21

SP - 33

EP - 39

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this